Evidence map›Paper›PMID 29567995›Full record

ArticleScientific reports2018

Molecular Camouflage of Plasmodium falciparum Merozoites by Binding of Host Vitronectin to P47 Fragment of SERA5.

Takahiro Tougan, Jyotheeswara R Edula, Eizo Takashima, Masayuki Morita, Miki Shinohara, Akira Shinohara, Takafumi Tsuboi, Toshihiro Horii

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Frontiers in immunology · 2023
    Article
  6. Review
  7. Red Blood Cell BCL-xMicroorganisms · 2022
    Article
  8. African-specific polymorphisms inFrontiers in cellular and infection microbiology · 2022
    Article
  9. Assessment of MixedCancers · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. [Development of malaria vaccines-state of the art].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2020
    Review
  16. Frontiers in microbiology · 2019
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Takahiro TouganDepartment of Molecular Protozoology, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Jyotheeswara R EdulaDepartment of Molecular Protozoology, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Eizo TakashimaDivision of Malaria Research, Proteo-Science Center, Ehime University, 3 Bunkyo-cho, Matsuyama, Ehime, 790-8577, Japan.ORCID 0000-0001-9070-8499
Masayuki MoritaDivision of Malaria Research, Proteo-Science Center, Ehime University, 3 Bunkyo-cho, Matsuyama, Ehime, 790-8577, Japan.
Miki ShinoharaDepartment of Advanced Bioscience, Faculty of Agriculture, Kindai University, 3327-204 Nakamachi, Nara, Nara, 631-8505, Japan.
Akira ShinoharaDepartment of Integrated Protein Functions, Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.ORCID 0000-0003-4207-8247
Takafumi TsuboiDivision of Malaria Research, Proteo-Science Center, Ehime University, 3 Bunkyo-cho, Matsuyama, Ehime, 790-8577, Japan.
Toshihiro HoriiDepartment of Molecular Protozoology, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan. horii@biken.osaka-u.ac.jp.
Ehime University · JPThe University of Osaka · JPKindai University · JPProtein Research Foundation · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The malaria parasite Plasmodium falciparum proliferates in the blood stream where the host immune system is most active. To escape from host immunity, P. falciparum has developed a number of evasion mechanisms. Serine repeat antigen 5 (SERA5) is a blood stage antigen highly expressed at late trophozoite and schizont stages. The P47 N-terminal domain of SERA5, the basis of SE36 antigen of the blood stage vaccine candidate under clinical trials, covers the merozoite surface. Exploring the role of the P47 domain, screening of serum proteins showed that vitronectin (VTN) directly binds to 20 residues in the C-terminal region of SE36. VTN co-localized with P47 domain in the schizont and merozoite stages. Phagocytosis assay using THP-1 cells demonstrated that VTN bound to SE36 prevented engulfment of SE36-beads. In addition, several serum proteins localized on the merozoite surface, suggesting that host proteins camouflage merozoites against host immunity via binding to VTN.

Indexed as

AnimalsAntigensAntigens, ProtozoanHost-Parasite InteractionsHumansImmunityMalaria, FalciparumMerozoitesMicePhagocytosisPlasmodium falciparumProtein BindingVitronectinAntigensAntigens, Protozoanserine repeat antigen 5, Plasmodium falciparumVitronectin

Identifiers

PMID29567995
PMCPMC5864917
OpenAlexW2807426073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.